Clinical testing of JWATM214 by JW Therapeutics in people with advanced hepatocellular carcinoma has begun.

The first patient infusion and the start of a clinical investigation of JWATM214 in people with advanced hepatocellular carcinoma (HCC) were both reported by JW Therapeutics, an independent and creative biotechnology business. Primary hepatic carcinoma is a common malignant tumour…